睿知中国医院研究地图
候选清单

正在招募乳腺癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

ClinicalTrials.gov 上登记的一项乳腺癌开放试验。牵头方不是本站收录的医院;本站收录的 57 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 57

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心新疆医科大学附属肿瘤医院Affiliated Cancer Hospital of Xinjiang Medical University乌鲁木齐医院页面
  2. 研究中心青岛大学附属医院Affiliated Hospital of Qingdao University青岛医院页面
  3. 研究中心西南医科大学附属医院Affiliated Hospital of Southwest Medical University泸州医院页面
  4. 研究中心徐州医科大学附属医院Affiliated Hospital of Xuzhou Medical University徐州医院页面
  5. 研究中心Anhui Provincial Cancer Hospital城市未列出医院页面
  6. 研究中心安阳市肿瘤医院Anyang Tumor Hospital安阳医院页面
  7. 研究中心蚌埠医学院第一附属医院First Affiliated Hospital of Bengbu Medical University蚌埠医院页面
  8. 研究中心重庆医科大学附属第一医院First Affiliated Hospital of Chongqing Medical University重庆医院页面
  9. 研究中心河南科技大学第一附属医院First Affiliated Hospital of Henan University of Science and Technology洛阳医院页面
  10. 研究中心温州医科大学附属第一医院First Affiliated Hospital of Wenzhou Medical University温州医院页面
  11. 研究中心西安交通大学第一附属医院First Affiliated Hospital of Xi'an Jiaotong University西安医院页面
  12. 研究中心厦门大学附属第一医院First Affiliated Hospital of Xiamen University厦门医院页面
  13. 研究中心浙江中医药大学附属第一医院(浙江省中医院)First Affiliated Hospital of Zhejiang Chinese Medical University杭州医院页面
  14. 研究中心郑州大学第一附属医院First Affiliated Hospital of Zhengzhou University郑州医院页面
  15. 研究中心浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面
  16. 研究中心吉林大学第一医院First Hospital of Jilin University长春医院页面
  17. 研究中心兰州大学第一医院First Hospital of Lanzhou University兰州医院页面
  18. 研究中心河北医科大学第四医院Fourth Hospital of Hebei Medical University石家庄医院页面
  19. 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面
  20. 研究中心福建省肿瘤医院Fujian Cancer Hospital福州医院页面
  21. 研究中心福建医科大学附属协和医院Fujian Medical University Union Hospital福州医院页面
  22. 研究中心广东省人民医院Guangdong Provincial People's Hospital广州医院页面
  23. 研究中心广西医科大学附属肿瘤医院Guangxi Medical University Cancer Hospital南宁医院页面
  24. 研究中心海南医学院附属医院/海南省人民医院Hainan General Hospital / Hainan Medical University hospitals海口医院页面
  25. 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
  26. 研究中心复旦大学附属华山医院Huashan Hospital上海医院页面
  27. 研究中心湖北省肿瘤医院Hubei Cancer Hospital武汉医院页面
  28. 研究中心江苏省人民医院(南医大一附院)Jiangsu Province Hospital南京医院页面
  29. 研究中心江西省肿瘤医院Jiangxi Cancer Hospital南昌医院页面
  30. 研究中心辽宁省肿瘤医院Liaoning Cancer Hospital & Institute沈阳医院页面
  31. 研究中心临沂市肿瘤医院Linyi Cancer Hospital临沂医院页面
  32. 研究中心梅州市人民医院Meizhou People's Hospital梅州医院页面
  33. 研究中心Nanchang People's Hospital南昌医院页面
  34. 研究中心南京鼓楼医院Nanjing Drum Tower Hospital南京医院页面
  35. 研究中心宁波市医疗中心李惠利医院Ningbo Medical Center Lihuili Hospital宁波医院页面
  36. 研究中心北京协和医院Peking Union Medical College Hospital北京医院页面
  37. 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
  38. 研究中心北京大学深圳医院Peking University Shenzhen Hospital深圳医院页面
  39. 研究中心西安交通大学第二附属医院Second Affiliated Hospital of Xi'an Jiaotong University西安医院页面
  40. 研究中心大连医科大学附属第二医院Second Hospital of Dalian Medical University大连医院页面
  41. 研究中心中南大学湘雅二医院Second Xiangya Hospital长沙医院页面
  42. 研究中心四川省肿瘤医院Sichuan Cancer Hospital成都医院页面
  43. 研究中心四川省人民医院Sichuan Provincial People's Hospital成都医院页面
  44. 研究中心浙江大学医学院附属邵逸夫医院Sir Run Run Shaw Hospital杭州医院页面
  45. 研究中心中山大学孙逸仙纪念医院Sun Yat-sen Memorial Hospital广州医院页面
  46. 研究中心天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面
  47. 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
  48. 研究中心四川大学华西医院West China Hospital成都医院页面
  49. 研究中心中南大学湘雅医院Xiangya Hospital长沙医院页面
  50. 研究中心襄阳市中心医院Xiangyang Central Hospital襄阳医院页面
  51. 研究中心空军军医大学西京医院Xijing Hospital西安医院页面
  52. 研究中心上海交通大学医学院附属新华医院Xinhua Hospital上海医院页面
  53. 研究中心徐州市中心医院Xuzhou Central Hospital徐州医院页面
  54. 研究中心云南省肿瘤医院Yunnan Cancer Hospital昆明医院页面
  55. 研究中心浙江省肿瘤医院Zhejiang Cancer Hospital杭州医院页面
  56. 研究中心浙江省人民医院Zhejiang Provincial People's Hospital杭州医院页面
  57. 研究中心南方医科大学珠江医院Zhujiang Hospital广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT05696626,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histological or cytological confirmation of ER+/HER2 - disease

    入选标准第 3 条

  3. History of Grade 3 or Grade 4 interstitial lung disease (ILD) on previous therapy.

    排除标准第 2 条

    Radiotherapy within 30 days prior to Visit 0 (Day 1) except in case of localized radiotherapy for analgesic purposes or for lytic lesions at risk of fracture, which can then be completed within 7 days prior to Visit 0 (Day 1). Subjects must have recovered from radiotherapy toxicities prior to Visit 0 (Day 1).

    排除标准第 6 条

    History of a pulmonary embolus (PE), deep vein thrombosis (DVT), or any known thrombophilia, unless the event occurred greater than 6 months prior to screening and the subject is treated with chronic anticoagulant therapy such as apixaban (Eliquis) or rivaroxaban (Xarelto).

    排除标准第 9 条

  4. Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1

    入选标准第 8 条

  5. Locally advanced or metastatic breast cancer with at least 1 measurable (according to RECIST 1.1) lesion with or without non-measurable lesions.

    入选标准第 6 条

    Central nervous system disease stable for >3 months prior to registration as documented by magnetic resonance imagining (MRI).

    入选标准第 15 条

  6. Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).

    排除标准第 15 条

    History of malignancy within the past 5 years (excluding breast cancer), except basal cell or squamous cell carcinoma of the skin curatively treated by surgery.

    排除标准第 16 条

  7. Positive serum pregnancy test (only if premenopausal).

    排除标准第 17 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05696626,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Pre- or postmenopausal women or men.
  2. Locally advanced and/or metastatic ER+ breast cancer with radiological or clinical evidence of progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease.
  3. Histological or cytological confirmation of ER+/HER2 - disease
  4. No evidence of progression for at least 6 months on an AI/CDKi combination for advanced breast cancer.
  5. At least 1 or more ESR1 point mutations in the ESR1 ligand binding domain as assessed in cell- free ctDNA obtained from a blood or breast cancer tissue.
  6. Locally advanced or metastatic breast cancer with at least 1 measurable (according to RECIST 1.1) lesion with or without non-measurable lesions.
  7. Subjects may have received 1 cytotoxic chemotherapy regimen in the metastatic disease setting prior to study entry, but must have recovered from chemotherapy acute toxicity excluding alopecia and Grade 2 peripheral neuropathy.
  8. Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1
  9. Adequate organ function
  10. Able to swallow tablets
  11. Brain metastases are allowed only if the following 4 parameters hold:
  12. Asymptomatic,
  13. Definitively treated (e.g., radiotherapy, surgery),
  14. Not requiring steroids up to 4 weeks before study treatment initiation, AND
  15. Central nervous system disease stable for >3 months prior to registration as documented by magnetic resonance imagining (MRI).
  16. Able to understand and voluntarily sign a written informed consent before any screening procedures.
  17. Every attempt should be made to obtain a biopsy of metastatic breast cancer tissue, when safe and feasible, to provide histological or cytological confirmation of ER+/HER2- disease as assessed by a local laboratory, according to American Society of Clinical Oncology/College of American Pathologists guidelines, using slides, paraffin blocks, or paraffin samples. If a biopsy is done, it may undergo genomic testing at some point to assess for ESR1 mutations and correlation with ctDNA results. If a biopsy is not possible or inappropriate from a clinical standpoint, the ER and HER2 status from the subject's most recent biopsy must confirm that the subject is ER+ and HER2

排除标准:Exclusion Criteria:

  1. Lymphangitic carcinomatosis involving the lung.
  2. History of Grade 3 or Grade 4 interstitial lung disease (ILD) on previous therapy.
  3. Visceral crisis in need of cytotoxic chemotherapy as assessed by the investigator.
  4. Prior progression of disease on abemaciclib, fulvestrant, or other selective estrogen receptor degrader (SERD) therapy.
  5. Subjects with a known hypersensitivity to fulvestrant or to any of the excipients
  6. Radiotherapy within 30 days prior to Visit 0 (Day 1) except in case of localized radiotherapy for analgesic purposes or for lytic lesions at risk of fracture, which can then be completed within 7 days prior to Visit 0 (Day 1). Subjects must have recovered from radiotherapy toxicities prior to Visit 0 (Day 1).
  7. Known RB1 mutations or deletions that in the opinion of the investigator confer resistance to CDK4/6i. (Screening for RB1 mutation is not required for entry.)
  8. History of long QTc (Q-T interval corrected for heart rate) syndrome or a QTc of >480 msec.
  9. History of a pulmonary embolus (PE), deep vein thrombosis (DVT), or any known thrombophilia, unless the event occurred greater than 6 months prior to screening and the subject is treated with chronic anticoagulant therapy such as apixaban (Eliquis) or rivaroxaban (Xarelto).
  10. Lasofoxifene is not recommended for use in subjects with conditions that place them at increased risk for VTEs (such as severe congestive heart failure [CHF] or prolonged immobilization).
  11. On concomitant strong CYP3A4 inhibitors.
  12. On strong and moderate CYP3A4 inducers.
  13. Any significant co-morbidity that would impact the study or the subject's safety, including subjects with significant malabsorption.
  14. Active systemic bacterial or fungal infection (requiring intravenous [IV] antibiotics or antifungals at the time of initiating study treatment).
  15. Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).
  16. History of malignancy within the past 5 years (excluding breast cancer), except basal cell or squamous cell carcinoma of the skin curatively treated by surgery.
  17. Positive serum pregnancy test (only if premenopausal).
  18. Sexually active premenopausal women and men unwilling to use double-barrier contraception.
  19. Women who are breast feeding
  20. History of non-compliance to medical regimens.
  21. Unwilling or unable to comply with the protocol.
  22. Current participation in any clinical research trial involving an investigational drug or device within the last 30 days.
  23. Subjects with a history of familial hypertriglyceridemia or fasting triglyceride levels >880 mg/dL at screening.
  24. Fasting triglyceride level >300 mg/dL and ≤880 mg/dL at screening. Subjects may be retested and enrolled if they have a repeat fasting triglyceride level less than or equal to 300 mg/dL prior to enrollment (e.g., after adjustment with diet and/or treatment).
  25. Fasting cholesterol level >400 mg/dL at screening. Subjects may be retested and enrolled if they have a repeat fasting cholesterol level less than or equal to 400 mg/dL prior to enrollment (e.g., after adjustment with diet and/or treatment).

引自 ClinicalTrials.gov, NCT05696626, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05696626,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT05696626